ONC
insider transactionsBeOne Medicines Ltd. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-21.7K
0 buy · 21.7K sell
Net value · 90d
-$5.8M
$0 in · $5.8M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
32
0 buy · 21.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SVP, General Counsel
$156.9K
590 sh · $265.98
Own -100%
-
Sell·S
Lai Wang KEY
President, Global Head of R&D
$310.2K
1.2K sh · $265.39
Own -100%
-
Sell·S
Xiaobin Wu KEY
President and COO
$362.0K
1.4K sh · $266.76
Own -100%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$88.8K
333 sh · $266.69
Own -100%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$454.8K
1.7K sh · $265.99
Own -84%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$437.0K
1.6K sh · $264.87
Own -45%
-
Grant·A
Director
$0
11.0K sh
Own New
-
Grant·A
Director
$0
2.2K sh
Own +88%
-
Grant·A
Director
$0
19.0K sh
Own New
-
Grant·A
Director
$0
19.0K sh
Own +474500%
-
Grant·A
Aaron Rosenberg KEY
Chief Financial Officer
$0
137.9K sh
Own New
-
Sell·S
Aaron Rosenberg KEY
Chief Financial Officer
$162.6K
631 sh · $257.74
Own -100%
-
Grant·A
Aaron Rosenberg KEY
Chief Financial Officer
$0
71.2K sh
Own +22%
-
Grant·A
SVP, General Counsel
$0
87.3K sh
Own New
-
Sell·S
SVP, General Counsel
$110.3K
428 sh · $257.64
Own -100%
-
Grant·A
SVP, General Counsel
$0
45.1K sh
Own +15%
-
Grant·A
Director
$0
19.0K sh
Own +35%
-
Grant·A
Director
$0
19.0K sh
Own +35%
-
Grant·A
Lai Wang KEY
President, Global Head of R&D
$0
229.8K sh
Own New
-
Sell·S
Lai Wang KEY
President, Global Head of R&D
$197.3K
756 sh · $261.00
Own -100%
-
Grant·A
Lai Wang KEY
President, Global Head of R&D
$0
118.6K sh
Own +7%
-
Grant·A
Xiaobin Wu KEY
President and COO
$0
229.8K sh
Own New
-
Sell·S
Xiaobin Wu KEY
President and COO
$163.5K
626 sh · $261.20
Own -100%
-
Grant·A
Xiaobin Wu KEY
President and COO
$0
118.6K sh
Own +10%
-
Grant·A
Director
$0
193.5K sh
Own New
-
Grant·A
Director
$0
99.9K sh
Own +2%
-
Grant·A
Director
$0
19.0K sh
Own +99%
-
Grant·A
Director
$0
19.0K sh
Own +29%
-
Grant·A
John Oyler KEY
Chief Executive Officer
$0
344.7K sh
Own New
-
Sell·S
John Oyler KEY
Chief Executive Officer
$38.6K
149 sh · $258.81
Own -100%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$51.7K
200 sh · $258.28
Own -57%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$221.3K
859 sh · $257.59
Own -71%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$189.9K
741 sh · $256.23
Own -38%
-
Grant·A
John Oyler KEY
Chief Executive Officer
$0
177.9K sh
Own +3%
-
Sell·S
Principal Accounting Officer
$30.9K
120 sh · $257.53
Own -100%
-
Sell·S
Principal Accounting Officer
$12.6K
49 sh · $256.39
Own -29%
-
Grant·A
Principal Accounting Officer
$0
31.2K sh
Own +46%
-
Grant·A
Director
$0
19.0K sh
Own +69%
-
Sell·S
SVP, General Counsel
$43.4K
160 sh · $271.26
Own -100%
-
Sell·S
SVP, General Counsel
$192.1K
711 sh · $270.24
Own -82%
-
Sell·S
Lai Wang KEY
President, Global Head of R&D
$10.8K
40 sh · $270.73
Own -100%
-
Sell·S
Lai Wang KEY
President, Global Head of R&D
$357.4K
1.3K sh · $269.34
Own -97%
-
Sell·S
Xiaobin Wu KEY
President and COO
$10.8K
40 sh · $270.55
Own -100%
-
Sell·S
Xiaobin Wu KEY
President and COO
$388.9K
1.4K sh · $269.33
Own -97%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$303.7K
1.1K sh · $271.14
Own -100%
-
Sell·S
John Oyler KEY
Chief Executive Officer
$1.0M
3.8K sh · $270.38
Own -77%
-
Sell·S
Principal Accounting Officer
$9.8K
36 sh · $272.08
Own -100%
-
Sell·S
Principal Accounting Officer
$27.1K
100 sh · $271.06
Own -74%
-
Sell·S
Director
$65.6K
235 sh · $279.13
Own -100%
-
Sell·S
Director
$65.6K
212 sh · $309.60
Own -100%
-
Sell·S
Director
$65.6K
212 sh · $309.51
Own -100%
-
Sell·S
Director
$65.6K
212 sh · $309.59
Own -100%
-
Exercise·M
SVP, General Counsel · 10b5-1
$0
1.3K sh
Own +1%
-
Exercise·M
SVP, General Counsel · 10b5-1
$0
1.7K sh
Own +2%
-
Exercise·M
SVP, General Counsel · 10b5-1
$0
1.3K sh
Own +7%
-
Sell·S
SVP, General Counsel · 10b5-1
$103.2K
332 sh · $310.72
Own -100%
-
Exercise·M
SVP, General Counsel · 10b5-1
$15.6K
98 sh · $159.03
Own +42%
-
Exercise·M
SVP, General Counsel · 10b5-1
$28.4K
133 sh · $213.32
Own +132%
-
Exercise·M
SVP, General Counsel · 10b5-1
$19.6K
101 sh · $194.47
Own New
-
Exercise·M
SVP, General Counsel · 10b5-1
$0
1.3K sh
Own +1%
-
Exercise·M
SVP, General Counsel · 10b5-1
$0
1.7K sh
Own +2%
-
Exercise·M
SVP, General Counsel · 10b5-1
$0
1.3K sh
Own +7%
-
Sell·S
SVP, General Counsel · 10b5-1
$103.4K
332 sh · $311.59
Own -100%
-
Exercise·M
SVP, General Counsel · 10b5-1
$15.6K
98 sh · $159.03
Own +42%
-
Exercise·M
SVP, General Counsel · 10b5-1
$28.4K
133 sh · $213.32
Own +132%
-
Exercise·M
SVP, General Counsel · 10b5-1
$19.6K
101 sh · $194.47
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Chan Henry Lee | Sell S | 590 | $156.9K |
| Jun 16, 2026 | Lai Wang KEY | Sell S | 1.2K | $310.2K |
| Jun 16, 2026 | Xiaobin Wu KEY | Sell S | 1.4K | $362.0K |
| Jun 16, 2026 | John Oyler KEY | Sell S | 333 | $88.8K |
| Jun 16, 2026 | John Oyler KEY | Sell S | 1.7K | $454.8K |
| Jun 16, 2026 | John Oyler KEY | Sell S | 1.6K | $437.0K |
| Jun 15, 2026 | Olivier Brandicourt | Grant A | 11.0K | $0 |
| Jun 15, 2026 | Olivier Brandicourt | Grant A | 2.2K | $0 |
| Jun 11, 2026 | Elizabeth Fisher Mooney | Grant A | 19.0K | $0 |
| Jun 11, 2026 | Charles Lazelle Sawyers | Grant A | 19.0K | $0 |
| Jun 11, 2026 | Aaron Rosenberg KEY | Grant A | 137.9K | $0 |
| Jun 11, 2026 | Aaron Rosenberg KEY | Sell S | 631 | $162.6K |
| Jun 11, 2026 | Aaron Rosenberg KEY | Grant A | 71.2K | $0 |
| Jun 11, 2026 | Chan Henry Lee | Grant A | 87.3K | $0 |
| Jun 11, 2026 | Chan Henry Lee | Sell S | 428 | $110.3K |
| Jun 11, 2026 | Chan Henry Lee | Grant A | 45.1K | $0 |
| Jun 11, 2026 | Margaret Dugan | Grant A | 19.0K | $0 |
| Jun 11, 2026 | Alessandro Riva | Grant A | 19.0K | $0 |
| Jun 11, 2026 | Lai Wang KEY | Grant A | 229.8K | $0 |
| Jun 11, 2026 | Lai Wang KEY | Sell S | 756 | $197.3K |
| Jun 11, 2026 | Lai Wang KEY | Grant A | 118.6K | $0 |
| Jun 11, 2026 | Xiaobin Wu KEY | Grant A | 229.8K | $0 |
| Jun 11, 2026 | Xiaobin Wu KEY | Sell S | 626 | $163.5K |
| Jun 11, 2026 | Xiaobin Wu KEY | Grant A | 118.6K | $0 |
| Jun 11, 2026 | Xiaodong Wang | Grant A | 193.5K | $0 |
| Jun 11, 2026 | Xiaodong Wang | Grant A | 99.9K | $0 |
| Jun 11, 2026 | Shalini Sharp | Grant A | 19.0K | $0 |
| Jun 11, 2026 | Anthony C Hooper | Grant A | 19.0K | $0 |
| Jun 11, 2026 | John Oyler KEY | Grant A | 344.7K | $0 |
| Jun 11, 2026 | John Oyler KEY | Sell S | 149 | $38.6K |
| Jun 11, 2026 | John Oyler KEY | Sell S | 200 | $51.7K |
| Jun 11, 2026 | John Oyler KEY | Sell S | 859 | $221.3K |
| Jun 11, 2026 | John Oyler KEY | Sell S | 741 | $189.9K |
| Jun 11, 2026 | John Oyler KEY | Grant A | 177.9K | $0 |
| Jun 11, 2026 | Titus B. Ball | Sell S | 120 | $30.9K |
| Jun 11, 2026 | Titus B. Ball | Sell S | 49 | $12.6K |
| Jun 11, 2026 | Titus B. Ball | Grant A | 31.2K | $0 |
| Jun 11, 2026 | Olivier Brandicourt | Grant A | 19.0K | $0 |
| Jun 8, 2026 | Chan Henry Lee | Sell S | 160 | $43.4K |
| Jun 8, 2026 | Chan Henry Lee | Sell S | 711 | $192.1K |
| Jun 8, 2026 | Lai Wang KEY | Sell S | 40 | $10.8K |
| Jun 8, 2026 | Lai Wang KEY | Sell S | 1.3K | $357.4K |
| Jun 8, 2026 | Xiaobin Wu KEY | Sell S | 40 | $10.8K |
| Jun 8, 2026 | Xiaobin Wu KEY | Sell S | 1.4K | $388.9K |
| Jun 8, 2026 | John Oyler KEY | Sell S | 1.1K | $303.7K |
| Jun 8, 2026 | John Oyler KEY | Sell S | 3.8K | $1.0M |
| Jun 8, 2026 | Titus B. Ball | Sell S | 36 | $9.8K |
| Jun 8, 2026 | Titus B. Ball | Sell S | 100 | $27.1K |
| Jun 1, 2026 | Qingqing Yi | Sell S | 235 | $65.6K |
| May 22, 2026 | Margaret Dugan | Sell S | 212 | $65.6K |
| May 22, 2026 | Alessandro Riva | Sell S | 212 | $65.6K |
| May 22, 2026 | Corazon (Corsee) D. Sanders | Sell S | 212 | $65.6K |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 1.3K | $0 |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 1.7K | $0 |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 1.3K | $0 |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Sell S | 332 | $103.2K |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 98 | $15.6K |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 133 | $28.4K |
| May 13, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 101 | $19.6K |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 1.3K | $0 |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 1.7K | $0 |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 1.3K | $0 |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Sell S | 332 | $103.4K |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 98 | $15.6K |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 133 | $28.4K |
| Apr 8, 2026 | Chan Henry Lee 10b5-1 | Exercise M | 101 | $19.6K |
About ONC insider trading
This page tracks insider transactions for BeOne Medicines Ltd. (ONC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.